好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hybrid Concept Elicitation and Cognitive Debriefing of Patient-reported Outcome Measures in Patients with Menstrual Migraine
Headache
P8 - Poster Session 8 (11:45 AM-12:45 PM)
15-003

Cognitive debriefing and content validation of the Functional Disability Scale (FDS), Activity Level Scale (ALS), Cognitive Function Scale (CFS), and PROMIS Cognitive Function Abilities-Short Form 6a (CFA-SF6a) for interpretability, clarity, relevance, and minimum meaningful improvement in participants with menstrual migraine (MM).

Women with MM have attacks in association with most of their menstrual cycles. Clarifying the translational value of existing patient-reported outcome measures (PROMs) in reflecting the experience of individuals with MM will improve the utility of data collected in clinical trials.

Adults with MM (≥4 attacks/month, at least two thirds associated with menstruation, and <15 monthly headache days) were recruited through an online platform. Semi-structured interviews queried the content validity of the FDS, ALS, CFS, and CFA-SF6a. Participants also estimated the minimum change necessary to achieve meaningful improvement on each PROM.

Participants (n=20) had a mean (SD) age of 39.2 (7.8) years and were 100% (20/20) female and 90% (18/20) White; the mean (SD) duration of migraine was 12.3 (8.9) years. Participants considered the CFS, FDS, ALS, and CFA-SF6a to be relevant, clear, and interpretable. The proportions endorsing a 1-point item-level change as meaningful improvement were 92% (12/13) on the CFS, 100% (14/14) on the FDS, and 100% (11/11) on the ALS. A 1-point change on the CFA-SF6a would be meaningful for the following proportions of participants: 83% (10/12, clarity/ease of thinking); 90% (9/10, memory); 92% (11/12, thinking speed); 94% (15/16, mental acuity); 100% (14/14, concentration); and 100% (14/14, keeping track of activities).

These qualitative data support the content validity of the FDS, ALS, CFS, and CFA-SF6a in adults with MM and suggest they may be fit for purpose in a clinical trial setting. Most participants indicated a 1-point item-level improvement on each PROM is meaningful. These proposed thresholds can complement those derived from statistical methods (e.g., anchor-based analyses).

Authors/Disclosures
Krutika Jariwala-Parikh, PhD (AbbVie)
PRESENTER
Dr. Jariwala-Parikh has received personal compensation for serving as an employee of AbbVie. Dr. Jariwala-Parikh has stock in AbbVie.
Colleen V. Castro Ms. Castro has received personal compensation for serving as an employee of AbbVie. An immediate family member of Ms. Castro has received personal compensation for serving as an employee of ClickHouse. An immediate family member of Ms. Castro has received personal compensation for serving as an employee of ElasticSearch. Ms. Castro has stock in AbbVie. An immediate family member of Ms. Castro has stock in ElasticSearch.
Elizabeth Hribal The institution of Miss Hribal has received research support from AbbVie.
Gina Ahmadyar (AbbVie) Ms. Ahmadyar has received personal compensation for serving as an employee of AbbVie.
Chris Evans, PhD The institution of Dr. Evans has received research support from AbbVie.
Sean Delaney The institution of Mr. Delaney has received research support from AbbVie.
Marc Bacharach The institution of Mr. Bacharach has received research support from AbbVie.
Amit Bodhani, Other (Abbvie) Mr. Bodhani has received personal compensation for serving as an employee of AbbVie. Mr. Bodhani has stock in AbbVie.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology) Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.